TIMP1 and cranioectodermal dysplasia: The TIMP-GLIA study (NCT04530123) is a phase 2 clinical trial evaluating the safety and efficacy of OIT with TIMP-GLIA, a combination therapy consisting of two recombinant gluten-specific T cell epitopes, in patients with CeD.